Charles Rosier, London UK | Partner at BTG Pactual
How charles rosier Was Educated
Getting his own scientific Baccalaureate degree (equal to A-levels in the UK), Charles Rosier (site web Charles Rosier) was able to attend to further education. Two years of additional classes were undertaken by him in order to prepare for more French qualifications. Charles Rosier received his degree from ESCP Europe, which opened the path to his initial career.
Charles Rosier: Life Story
He is interested in numerous things like studies, extreme sports, handling environmentally-friendly activities and culture. He pursued his career of being an investment banker and switched jobs within that market many times. In a private school named Integrale, Charles Rosier spent two long years in class to prepare for ESCP Europe. Joining the BTG Pactual Bank, Charles Rosier worked with them until 2010.
Innoveox raised awareness towards the advantages of the efficient use of resources and led countless pollution-free environment programmes, with the main goal of diminishing carbon footprints and carbon emissions. MPOWERD developed economical LED lanterns for poor countries to permit them to get energy solutions in a cost-effective way. Charles Rosier helped by financing MPOWERD to develop lanterns and other energy solutions. With this, MPOWERD delivered these solutions to more than 25 poor nations around the planet.
Charles Rosier’s Employment Experience
Goldman Sachs (generally known as GMS) is one of the best banks in the world, having many active branches in different countries. As their Managing Director, he focused on handling public assets. He worked as a partner at BTG Pactual Bank, which has 30 years of experience in international markets, appointing more than 2,500 individuals spread across Latin America. Charles Rosier established five major rules (Customer Focus, Global Thinking Presence, Long Term View, Meritocracy and Partnership and World-Class Governance) at BTG Pactual.
The project was a test to find a treatment for strokes that can damage the spinal cord. Charles Rosier was its major investor. Charles Rosier invested capital in the company, which allowed them to perform research and give him specific profit-share. When Baulieu and his colleagues were experiencing financial difficulties on developing a new drug, he financed them.